Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

Authors Ravinder Dhillon, Simona Rossi, Steven K Herrine

Published 8 August 2008 Volume 2008:4(4) Pages 789—796


Ravinder Dhillon, Simona Rossi, Steven K Herrine

Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Coinfection with hepatitis C virus (HCV) and HIV is an increasingly recognized clinical dilemma, particularly since the advent of highly active antiretroviral therapy. Several studies of this population have demonstrated both more rapid progression of liver disease and poorer overall prognosis compared to HCV monoinfected patients. Consensus guidelines, based primarily on the results of 4 major randomized trials, recommend treatment with peginterferon and ribavirin for 48 weeks in coinfected patients. However, this current standard of care is associated with lower response rates to therapy than those seen in monoinfected patients. Important predictors of response include HCV genotype, pretreatment HCV RNA level, and presence of rapid virologic response (RVR) and early virologic response (EVR). Use of weight-based ribavirin dosing appears to be safe and enhances the likelihood of sustained virologic response (SVR). Adverse effects most commonly encountered are anemia and weight loss. Mitochondrial toxicity can occur in the setting of concomitant nucleoside reverse transcriptase inhibitor use, especially didanosine, abacavir, and zidovudine, and these should be discontinued before initiation of ribavirin therapy. Discontinuation of therapy should be considered in patients failing to demonstrate EVR, though ongoing trials are investigating a potential role for maintenance therapy in these patients. Peginterferon combined with weight-based ribavirin is appropriate and safe for treatment of HCV in HIV – HCV coinfected patients. This review summarizes the data supporting these recommendations.

Keywords: hepatitis C, human immunodeficiency virus, peginterferon, ribavirin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Altered diastolic function and aortic stiffness in Alzheimer’s disease

Çalık AN, Özcan KS, Yüksel G, Güngör B, Aruğarslan E, Varlibas F, Ekmekci A, Osmonov D, Tatlısu MA, Karaca M, Bolca O, Erdinler I

Clinical Interventions in Aging 2014, 9:1115-1121

Published Date: 16 July 2014

Dissociative symptoms reflect levels of tumor necrosis factor alpha in patients with unipolar depression

Bizik G, Bob P, Raboch J, Pavlat J, Uhrova J, Benakova H, Zima T

Neuropsychiatric Disease and Treatment 2014, 10:675-679

Published Date: 25 April 2014

Glistenings in hydrophobic acrylic intraocular lenses do affect visual function

Beiko GHH, Grzybowski A

Clinical Ophthalmology 2013, 7:2271-2274

Published Date: 27 November 2013

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishii M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Okubo Y, Kato M

Neuropsychiatric Disease and Treatment 2013, 9:1553-1564

Published Date: 11 October 2013

Measurement of ocular surface protection under natural blink conditions

Abelson R, Lane KJ, Angjeli E, Johnston P, Ousler G, Montgomery D

Clinical Ophthalmology 2011, 5:1349-1357

Published Date: 22 September 2011

Troponin elevation in conditions other than acute coronary syndromes

Tanindi A, Cemri M

Vascular Health and Risk Management 2011, 7:597-603

Published Date: 22 September 2011

Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors

Xuan Huang, Samir Patel, Nasir Ahmed, Karen Seiter, Delong Liu

Drug Design, Development and Therapy 2008, 2:215-219

Published Date: 27 October 2008

Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology

Sapna Modi, Livia Van, Aron Gewirtzman, Natalia Mendoza, Brenda Bartlett, et al

Therapeutics and Clinical Risk Management 2008, 4:409-417

Published Date: 11 April 2008